Sunday 25 March 2012

World Health Organization-Therapeutic Drug-Novel Endocyte-Companion

Endocyte Receives USAN Approval for Nonproprietary Names of Novel Endocyte Drug Candidates

WEST LAFAYETTE, Ind., March 22, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the World Health Organization and the United States Adopted Names (USAN) Council have approved the nonproprietary name "vintafolide" (pronounced vin ta foe' lide) for Endocyte's therapeutic drug candidate EC145 and the nonproprietary name of "etarfolatide" (pronounced et" ar foe' la tide) for Endocyte's companion imaging agent EC20. Vintafolide and etarfolatide are currently being evaluated in the Phase 3 PROCEED trial for the treatment of women with folate-receptor positive platinum-resistant ovarian cancer. Etarfolatide is being used to ... read more..

No comments:

Post a Comment